LILRB1 and cancer: In addition, we found that Mo-TAMs heightened the expression of LILRB1, a hitherto uncharacterized inhibitory receptor in the context of MPM disease, that recognizes MHC class I complexes and impairs the ability of TAMs to clear different types of cancer cells both in vitro and in vivo [41].